Prognostic impact of an extravascular congestion score and its interaction with SGLT2 inhibitor therapy in patients hospitalized for acute heart failure.
A new scoring system helps identify heart failure patients who gain the most benefit from a newer diabetes drug.
INTRODUCTION AND OBJECTIVES: Congestion is the main driver of hospitalization and adverse outcomes in acute heart failure (AHF), with tissue-predominant volume expansion frequently persisting despite loop diuretic therap... SGLT2i use was not associated with improved outcomes in ECS 0 (HR, 1.21; P = .462) but was associated with numerically lower risk in ECS 1 (HR, 0.76; P = .065), and with a marked risk reduction in ECS 2 (HR, 0.45; P = .0...
What the study was
- Study design
- Prospective study
- Population
- patients
- Sample size
- 821
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Revista espanola de cardiologia (English ed.)
Why it surfaced
Score 7/10 [PROMISING_PRELIMINARY]: Prospective study (Journal Article) matched 'Cardiovascular-metabolic: GLP-1, SGLT2, '. Components — novelty:1/3, relevance:3/3, design:1/2, population:2/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.